PG · Procter & Gamble
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $156
Note written ·
Price against the kill line
8.8% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $156.00, on record since 10 November 2026. The shares are up 19.4% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $156, under the $163.00 to $169.00 range at which P&G executives sold shares after the 22 October 2026 report, which would erase the post-earnings gain; or a cut to the fiscal 2027 core EPS range of $6.89 to $7.11.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Consumer Staples
Quarter to 30 September 2026, filed 22 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 23,276
- Revenue, change on a year (%)
- +4.0
- Gross margin (%)
- 49.8
- Operating margin (%)
- 25.5
- Free cash flow, four quarters ($M)
- 15,340
- Net cash, cash less debt ($M)
- −23,560
- Price to earnings (×)
- 24.6
- Enterprise value to sales (×)
- 4.7
All filed numbers
What Procter & Gamble reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 23,276 | +4.0 | 49.8 | 25.5 |
| first filed | 21,204 | +1.5 | 48.5 | 18.6 |
| first filed | 21,235 | +7.4 | 49.5 | 21.5 |
| first filed | 22,208 | +1.5 | 51.2 | 24.2 |
| first filed | 22,386 | +3.0 | 51.4 | 26.2 |
| first filed | 20,889 | +1.7 | 49.1 | 20.8 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: 16,026 | 4,731 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −1.2 |
| Operating cash flow ($M) | 19,915 |
| Capital spending ($M) | 4,575 |
| Free cash flow ($M) | 15,340 |
| Cash and short-term investments ($M) | 15,365 |
| Debt ($M) non-current long-term debt plus current debt | 38,925 |
| Net cash, cash less debt ($M) | −23,560 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 6,620 |
| Inventory ($M) | 8,485 |
| Shareholders' equity ($M) including non-controlling interests | 55,337 |
| Market value ($M) | 393,560 |
| Enterprise value, market value plus net debt ($M) | 417,120 |
| Enterprise value to sales (×) | 4.7 |
| Enterprise value to operating income (×) | 21.0 |
| Price to earnings (×) | 24.6 |
| Price to book value (×) | 7.1 |
| Free-cash-flow yield (%) | 3.9 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 0.9% of shares outstanding sold short, 2.4 days of average trading to cover, −9.6% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $38.0M |
| 12 monthsfrom | $0 | $93.5M |
The thesis
Procter & Gamble is modestly more likely to beat the S&P 500 than to lag it over the next three months. Volume-led growth restarted in the fiscal first quarter, and Brent crude, the main threat to margins, still trades below the $100 a barrel the company's cost plan assumes. The 19 November 2026 Investor Day and the fiscal second-quarter report, expected around 21 January 2027, show whether the growth lasts and whether margins recover.
Management's estimate of about $1.4 billion in after-tax costs for fiscal 2027 assumes Brent at $100, Trefis reported from the 22 October 2026 earnings call. Brent hit a ten-week low of $91.50 on 10 November 2026, then rose about 3.3% to near $95.80 on 12 November 2026 after President Trump said Washington no longer needs a deal with Iran (Trading Economics). The gap to $100 has narrowed, and that narrowing is the part of the case most open to reversal.
The operating case rests on the quarter to 30 September 2026. Organic sales, which exclude currency moves and acquisitions, rose 4% after 0% in the prior quarter. Volume added about 2 points, and all 10 product categories and all six regions grew (P&G 8-K Exhibit 99.1, 22 October 2026). Core earnings per share (EPS), which leave out restructuring and other non-core items, were $2.00, up 1%.
The price already reflects much of the recovery. The shares closed at $168.03 on 12 November 2026, against an average analyst target of $174.04 from 25 analysts polled by S&P Global (StockAnalysis), and Trefis put the trailing multiple at 24.2 times earnings against 22.9 for the S&P 500 on 6 November 2026.
Bullish and bearish views on The Procter & Gamble Company
The bull case on The Procter & Gamble Company (PG), in brief: volume is growing again. The bear case: the oil relief is reversing.
Bull case
- Volume is growing again. Volume added about 2 points of the 4% organic growth in the fiscal first quarter, after adding nothing in the fourth quarter of fiscal 2026 (company releases, 22 October 2026 and 29 July 2026). Fabric & Home Care, Beauty and Grooming each grew about 5%.
- Oil remains under the cost assumption. Brent traded near $95.80 on 12 November 2026, under the $100 behind the roughly $1.4 billion cost estimate (Trading Economics; Trefis, 26 October 2026). Saudi Arabia reported a 26% rise in October output, and US crude stocks rose about 4.66 million barrels in the week to 6 November 2026, the largest build since August (Trading Economics).
- Guidance held despite higher costs. On 22 October 2026 management kept the $6.89 to $7.11 fiscal 2027 core EPS range while raising its after-tax cost estimate to about $1.4 billion from about $1 billion in July. Trefis reported on 27 October 2026 that management is confident of finishing inside the range.
- Price increases are still ahead. Pricing contributed 0.4 points of first-quarter sales growth (Trefis, 27 October 2026), and management plans price rises tied to new products (fiscal.ai, 2 November 2026).
- Buy-rated targets sit above the shares. On 23 October 2026 BNP Paribas raised its target to $189, Citigroup to $187 and Morgan Stanley to $185 (Benzinga), and Freedom Capital Markets upgraded to Buy with a $176 target (StockAnalysis).
Bear case
- The oil relief is reversing. Brent rose about 3.3% on 12 November 2026 as Iran's security council secretary said Tehran would not remove enriched nuclear material and Washington stepped back from talks (Trading Economics). A return above $100 puts the cost plan back under strain.
- Margins are still falling. Core gross margin fell 1.5 percentage points to 50.0% in the fiscal first quarter, and core EPS was flat on a currency-neutral measure (8-K Exhibit 99.1, 22 October 2026). Trefis put the total fiscal 2027 hit from costs, currency, interest and other items at $0.79 a share, 11% of fiscal 2026 core EPS (6 November 2026).
- One quarter of volume is a short record. Organic growth was 0% in the quarter to 30 June 2026, so the fiscal first quarter is the only quarter of renewed volume so far (company releases, 29 July 2026 and 22 October 2026).
- Executives keep selling into the rally. SEC Form 4 filings show eight officers sold between 23 October 2026 and 12 November 2026 at $163.00 to $169.00, including CEO Shailesh Jejurikar (35,000 shares at $163.09 on 23 October 2026) and CFO Andre Schulten (33,624 at $165.00 on 4 November 2026 and 30,677 at $169.00 on 5 November 2026). The latest, 2,250 shares at $168.47 by the head of Baby and Feminine Care, came on 12 November 2026.
- Neutral targets cluster at the price. Bernstein's Hold rating carries a $170 target (4 November 2026), and TD Cowen ($166), Piper Sandler ($167) and Barclays ($165) hold Hold-equivalent ratings with targets below the 12 November 2026 close (StockAnalysis, 23 October to 26 October 2026).
- Money is rotating toward cyclicals. Growth sectors led on 9 November 2026 and cyclicals led while defensives trailed on 11 November 2026 (Benzinga), a session in which P&G fell to $167.67 from $168.66.
Price setup
The shares closed at $168.03 on 12 November 2026, 1.5% below the 52-week intraday high of $170.52 set on 5 November 2026. They rose 17.0% over three months from the 14 August 2026 close of $144.55, and the 52-week closing low was $138.04 on 7 January 2026.
As of 12 November 2026, the 50-day moving average stood at $153.11 and the 200-day at $147.88, both well under the price. Closes since 5 November 2026 have held between $165.40 (6 November 2026) and $168.66 (10 November 2026).
Executive sales in SEC Form 4 filings map where the shares traded after the report: $163.09 on 23 October 2026, $164.43 to $165.00 on 30 October 2026, $163.00 on 3 November 2026, $165.00 on 4 November 2026, $169.00 on 5 November 2026 and $168.47 on 12 November 2026. The consensus target of $174.04 sits 3.6% above the last close (StockAnalysis). P&G funded itself with debt: $3.25 billion of US dollar notes on 30 October 2026 and a €3.25 billion offering closed on 4 November 2026 (fiscal.ai).
Catalysts ahead
- 19 November 2026: P&G Investor Day 2026, webcast from Cincinnati with CEO Shailesh Jejurikar and CFO Andre Schulten. The first public management update since 22 October 2026; comments on pricing, savings, long-term targets and the $6.89 to $7.11 core EPS range show how higher costs are being covered.
- ~21 January 2027 (est.): Fiscal second-quarter 2027 report. Shows whether volume-led organic growth lasts in the quarter management expects higher costs, and whether the $6.89 to $7.11 core EPS range holds.
What would change the view
A daily close below $156, under the $163.00 to $169.00 range at which P&G executives sold shares after the 22 October 2026 report, which would erase the post-earnings gain; or a cut to the fiscal 2027 core EPS range of $6.89 to $7.11.
The risks this note tracks, each with what would confirm it:
- Oil rebounds and cost inflation outruns the volume recovery. Confirmed by: Brent back above $100 through the January report, a rise in the after-tax cost estimate above about $1.4 billion, or management steering toward the $6.89 bottom of the core EPS range.
- The volume recovery proves to be a single quarter. Confirmed by: fiscal Q2 2027 organic growth near 1% with a volume contribution of zero or below.
- Planned price increases reduce the volume that drove the recovery. Confirmed by: fiscal Q2 2027 pricing contribution rising above 0.4 points while the volume contribution falls below the roughly 2 points of the first quarter.
- The re-rated valuation fades as executives sell and the price sits near neutral-rated targets. Confirmed by: further executive sales disclosed in SEC Form 4 filings while the shares fall toward the 50-day moving average, or Buy-rated firms cutting targets after Investor Day.
- Easing conflict and strong growth sectors draw money out of defensives into cyclicals and technology. Confirmed by: consumer staples ranking among the weakest sectors on up-market days through November, as on 9 November 2026 and 11 November 2026.
What it trades with
P&G trades with consumer staples and defensive sectors broadly. It tends to lead when defensives lead, as on 5 November 2026, and lag when growth and cyclical sectors lead, as on 9 November 2026 and 11 November 2026 (Benzinga).
Its cost outlook runs against oil. Brent is the outside price that most directly moves the fiscal 2027 cost estimate, so US-Iran diplomacy and Gulf shipping bear on the shares. Kimberly-Clark shares the same cost and sector exposure; Benzinga reported on 5 November 2026 that Nvidia's forward price-to-earnings ratio of 15.2 had fallen below Kimberly-Clark's 15.5, a measure of how far staples valuations have risen relative to technology.
The evidence, claim by claim (7)
- Fiscal Q1 2027 net sales were $23.3 billion, up 4%, and organic sales rose 4%, with volume adding about 2 points; all 10 categories and all six regions grew. P&G Q1 FY2027 earnings release (8-K Exhibit 99.1) · as of
- Fiscal Q1 2027 core EPS was $2.00, up 1% and flat on a currency-neutral measure; core gross margin fell 1.5 percentage points to 50.0%. P&G Q1 FY2027 earnings release (8-K Exhibit 99.1) · as of
- Fiscal 2027 core EPS guidance of $6.89 to $7.11 was kept; the after-tax cost estimate rose to about $1.4 billion from about $1 billion in July and assumes Brent crude at $100 a barrel. P&G Q1 FY2027 earnings release; Trefis report on the 22 October 2026 call · as of
- Brent crude rose about 3.3% to near $95.80 a barrel on 12 November 2026, from a ten-week low of $91.50 on 10 November 2026. Trading Economics Brent crude page · as of
- P&G traded at 24.2 times trailing earnings against 22.9 for the S&P 500, and at 4.4 times sales, up from 3.8 at the end of September. Trefis, 6 November 2026 · as of
- Eight P&G officers sold shares at $163.00 to $169.00 between 23 October 2026 and 12 November 2026, including the CEO (35,000 at $163.09) and the CFO (33,624 at $165.00 and 30,677 at $169.00). SEC Form 4 filings, 26 October to 12 November 2026 · as of
- The average analyst target is $174.04 from 25 analysts polled by S&P Global; Bernstein rates the shares Hold with a $170 target, set 4 November 2026. StockAnalysis PG forecast page · as of
Sources
- SEC EDGAR
- Trading Economics ·
- The Procter & Gamble Company (PG) Stock Forecast & Price Targets · stockanalysis.com
- Is Procter & Gamble Stock Riskier Than It Looks? · trefis.com ·
- How Bad Would Higher Oil Prices Be For Procter & Gamble Stock? · trefis.com ·
- One Unsettled Question Sits Under Procter & Gamble Stock · trefis.com ·
- PG to Webcast Presentation From PG Investor Day 2026 November 19 · us.pg.com
Related · shared themes
CPRI
Capri Holdings
Capri Holdings' Michael Kors turnaround gives the shares a modest edge over the S&P 500 after the 30 October 2026 beat-and-raise, despite a…
CROX
Crocs
Crocs, Inc. is more likely to lead the S&P 500 over three months: a third-quarter beat and a third guidance raise lifted full-year adjusted…
CRSR
Corsair Gaming
Corsair Gaming's recovery case holds after it beat third-quarter guidance and raised its 2026 outlook on 5 November 2026; the…
EL
Estee Lauder Companies
Estée Lauder's turnaround now shows in sales as well as margins, with first-quarter organic sales up 6% and the fiscal 2027 outlook raised…
See also · stocks to watch